Delayed terminal ileal perforation in a relapsed/refractory b-cell lymphoma patient with rapid remission following chimeric antigen receptor t-cell therapy

9Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.

Cite

CITATION STYLE

APA

Cui, Q., Xiao, L., Xiao, Y., Wang, J., & Wu, Z. (2018). Delayed terminal ileal perforation in a relapsed/refractory b-cell lymphoma patient with rapid remission following chimeric antigen receptor t-cell therapy. Cancer Research and Treatment, 50(4), 1462–1466. https://doi.org/10.4143/crt.2017.473

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free